Medidur fluocinolone acetonide intravitreal implant: Phase III data

Top-line data from a double-blind, international Phase III trial in 129 patients with recurrent non-infectious uveitis affecting the posterior segment of the eye with or without anterior uveitis showed that 0.18 mg intravitreal Medidur

Read the full 345 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE